The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second IL-6 inhibitor Kevzara [Regeneron / Sanofi]), and five oral JAK inhibitors—Xeljanz (Pfizer), Olumiant (Eli Lilly), Rinvoq (AbbVie), Jyseleca (Galapagos / Gilead / Eisai), and Smyraf (Astellas). The TNF-α inhibitors are the most widely prescribed biologics for RA that is refractory to conventional DMARDs, and the non-TNF-α biologics and JAK inhibitors largely compete for use in the TNF-refractory population. With the recent approval of an additional JAK inhibitor (Gilead / Galapagos’s Jyseleca) and biosimilars of several TNF and non-TNF biologics, marketers are facing fierce competition and increasing challenges to gain market share.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 28 country-specific interviews with thought leaders.
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA; number of diagnosed prevalent cases of RA by severity.
Emerging therapies: Phase III: 2 drugs; coverage of 7 select early-phase pipeline products.